The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
A DNA-repair prognostic signature for early-stage NSCLC patients, in IFCT-0002 trial of neoadjuvant chemotherapy.
Gerard Zalcman
No relevant relationships to disclose
Guenaelle Levallet
No relevant relationships to disclose
Pierre Fouret
No relevant relationships to disclose
Martine Antoine
No relevant relationships to disclose
Elisabeth Brambilla
Consultant or Advisory Role - Roche
Emmanuel Bergot
No relevant relationships to disclose
Francoise Galateau-Salle
No relevant relationships to disclose
Armelle Lavole
No relevant relationships to disclose
Elisabeth A. Quoix
No relevant relationships to disclose
Didier Debieuvre
No relevant relationships to disclose
Julien Mazieres
No relevant relationships to disclose
Denis Moro-Sibilot
No relevant relationships to disclose
Jean-Louis Pujol
No relevant relationships to disclose
Denis Braun
No relevant relationships to disclose
Michele Beau-Faller
No relevant relationships to disclose
Laurence Baudrin
No relevant relationships to disclose
Franck Morin
No relevant relationships to disclose
Virginie Westeel
Consultant or Advisory Role - Lilly; Roche
Research Funding - Roche
Other Remuneration - AstraZeneca; Boehringer Ingelheim; Chugai Pharma; Lilly; Roche